Ameriprise Financial Inc Adverum Biotechnologies, Inc. Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $38,778 - $391,013	40,394 New	40,394 $38,000
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $343,858 - $703,228	-43,090 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $140,185 - $334,583	-27,380 Reduced 38.85%	43,090 $496,000
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $717,974 - $2.18 Million	-137,018 Reduced 66.04%	70,470 $384,000
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $322,972 - $752,969	-63,328 Reduced 23.38%	207,488 $2.47 Million
Q1 2019 May 15, 2019	BUY	$3.03 - $6.02 $335,451 - $666,474	110,710 Added 69.15%	270,816 $1.42 Million
Q4 2018 Feb 14, 2019	BUY	$2.87 - $5.92 $459,504 - $947,827	160,106 New	160,106 $505,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.